• 2193 Citations
  • 26 Scopus h-Index
1990 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Evette S Radisky is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition

    Raeeszadeh-Sarmazdeh, M., Greene, K. A., Sankaran, B., Downey, G. P., Radisky, D. C. & Radisky, E. S., Jan 1 2019, In : Journal of Biological Chemistry. 294, 24, p. 9476-9488 13 p.

    Research output: Contribution to journalArticle

  • Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin

    Cohen, I., Coban, M., Shahar, A., Sankaran, B., Hockla, A., Lacham, S., Caulfield, T., Radisky, E. S. & Papo, N., Jan 1 2019, In : Journal of Biological Chemistry. 294, 13, p. 5105-5120 16 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Novel pathogenic PRSS1 variant p.Glu190Lys in a case of chronic pancreatitis

    Jancsó, Z., Oracz, G., Kujko, A. A., Kolodziejczyk, E., Radisky, E. S., Rygiel, A. M. & Sahin-Tóth, M., Jan 1 2019, In : Frontiers in Genetics. 10, FEB, 46.

    Research output: Contribution to journalArticle

    Open Access
  • PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma

    Ma, H., Hockla, A., Mehner, C., Coban, M., Papo, N., Radisky, D. C. & Radisky, E. S., Dec 1 2019, In : Scientific reports. 9, 1, 1844.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering

    Sananes, A., Cohen, I., Shahar, A., Hockla, A., De Vita, E., Miller, A. K., Radisky, E. S. & Papo, N., Jan 1 2018, In : Journal of Biological Chemistry. 293, 33, p. 12663-12680 18 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations